Drug Approval | May 10, 2024
Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
The product is used to treat amyotrophic lateral sclerosis
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
With this, for all our USFDA facilities, EIRs are in place
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Subscribe To Our Newsletter & Stay Updated
